This site is intended for healthcare professionals only
DiabetesontheNet Logo
Sign In / Register

Issue:

Share this article

The role of HDL-C in diabetes and the metabolic syndrome

Peter Stott

People with diabetes or the metabolic syndrome are at increased risk of myocardial infarction. The most important lipid intervention when reducing the risk of coronary heart disease is reduction of low-density lipoprotein cholesterol; however, there is similar evidence of risk reduction with an increased high-density-lipoprotein cholesterol (HDL-C) level. This article looks at the role of HDL-C in people with diabetes and the metabolic syndrome.

Reduction of low-density lipoprotein cholesterol (LDL-C) is the single most important lipid intervention that will reduce coronary heart disease (CHD). Epidemiological work has consistently shown that each 1% reduction in LDL-C results in a reduction of 1.0–1.5% in the risk of major cardiological events. In both primary and secondary prevention studies, meta-analysis of LDL-C lowering strategies has shown a 12–38 % reduction in LDL-C and a relative risk reduction of 19–35 % in overall risk (Hennekens and Ridker, 1999).

Benefit of raising HDL-C
There is similar convincing evidence in relation to the importance of high-density-lipoprotein cholesterol (HDL-C). HDL-C is the ‘scavenger’ lipoprotein. Its function is to transport excess cholesterol back to the liver for further metabolism. Every 2–3 % rise in HDL-C (around 0.03 mmol/l) has been associated with a reduction in risk of 2–4 %, independent of the level of LDL-C (Gordon et al, 1989; Phillips et al, 1993; Brown et al, 1990). The preventive effect of HDL-C seems more important in post- menopausal women. Meta-analysis of US studies suggests that an increase of 0.026 mmol/l (1mg/dL) is associated with a reduction in coronary events of 2% in men but 3% in women, independent of other risk factors, such as LDL-C (Sharrett et al, 2001; Gordon and Rifkind, 1989).

Studies of HDL-C
The metabolism of HDL-C and triglyceride are inextricably linked. Strategies that raise HDL-C are invariably associated with a reduction in triglycerides. In the Veterans Affairs HDL-C Intervention trial (VA-HIT; Rubins et al, 1999), the fibrate gemfibrozil was compared with placebo in men with dyslipidaemia typical of the metabolic syndrome. At one year, though mean LDL-C remained the same in both groups, mean HDL-C was 6% higher and mean triglyceride levels were 31 % lower in the fibrate group than in the group receiving placebo. These changes in the treatment arm were associated with a 22 % and 25 % reduction in myocardial infarction and stroke respectively. So reduction of HDL-C is associated with improvements not only in surrogate measures but also in outcomes.

Combined LDL-C/HDL-C strategies
The logical conclusion is that a therapeutic approach which combines lowering of LDL-C with raising of HDL-C could reduce risk of coronary events by 60–80%. This is of particular importance in type 2 diabetes, in pre- diabetes and in the metabolic syndrome, all of which are associated with a particularly atherogenic pattern of dyslipidaemia:

  • raised triglycerides 
  • unchanged or raised LDL-C rendered more atherogenic because of a raised triglyceride load (known as small dense LDL-C) 
  • lowered HDL-C, less able to ‘scavenge’ cholesterol effectively because of a high triglyceride load 
  • increased very-low density lipoprotein (containing triglyceride).

This particular pattern of dyslipidaemia goes some way to explaining why people in these groups are at especial risk of developing CHD and why patients with diabetes who have not yet suffered a myocardial infarction are at the same risk as people without diabetes who have (Watkins, 2003). The risk of CHD in patients with pre-diabetes and the metabolic syndrome is less well established. However, it is logical that increased risk should not suddenly begin with the diagnosis of full-blown diabetes, but rather that it should extend some way back through the duration of pre-diabetes metabolic imbalance. This is known to exist for 10 to 15 years before frank diabetes develops.

General Medical Services contract
The new General Medical Services contract has obscured the importance of HDL-C by focusing clinical attention upon LDL-C. For patients with both established CHD and diabetes, GPs now have a single lipid target of 5.0 mmol/l for LDL-C (British Medical Association, 2003). Authorities have argued that for patients at risk of CHD, and particularly those with diabetes and the metabolic syndrome, consideration of HDL-C should also be included (European Consensus Panel on HDL-C, 2004). Examples of the desirable lipid levels for patients at risk of CHD are shown in Table 1.

While there is a consensus that an HDL-C of >1.0 mmol/l should be achieved in patients with established CHD, some guidelines have suggested that in women it should be even higher (>1.3mmol/l) (Mosca et al, 2004; American Diabetes Association, 2004).

The ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol 2 study
Two therapies are particularly useful in raising HDL-C – the fibrates and nicotinic acid (niacin). The latter agent has a greater effect on HDL-C. Recent interest, therefore, has focused upon the combined benefits of statins plus nicotinic acid therapy in patients with a history of CHD. The results of the ARBITER 2 study (ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol; Taylor et al, 2004) were presented at the American Heart Association meeting in New Orleans in November 2004. These data showed that, compared with a statin alone, the combination of statin and prolonged-release nicotinic acid (Niaspan) significantly slowed progression of atherosclerosis, as measured by carotid intima-media thickness (CIMT), among individuals with established coronary risk and moderately low HDL-C.

In the patients taking a statin plus prolonged- release nicotinic acid, HDL-C increased by 21 % and CIMT remained unchanged. In the group taking statin alone, HDL-C was unchanged at one year and CIMT had progressed significantly. Somewhat surprisingly, the difference in CIMT between the two groups was only significant in those individuals who did not have insulin resistance. Nevertheless, the researchers concluded that the addition of prolonged-release nicotinic acid to statin therapy slowed the rate of progression of atherosclerosis among individuals with known CHD and moderately low HDL-C.

Concern has been expressed that nicotinic acid may increase the glucose level in patients with impaired fasting glucose (but not yet diabetes) or the metabolic syndrome, based upon earlier reports. However, recent analyses of pooled double-blind data have shown no increased effect other than that which would be expected from the natural progression to diabetes in this type of case (Insull et al, 2004).

Lifestyle and HDL-C
Several lifestyle changes have also been shown to raise HDL-C. Weight loss, exercise and stopping smoking will raise HDL-C. So too will food and drinks such as red wine, orange juice, beans, fish, olive oil, oat bran, onions, soy products and soluble fibre (Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III [ATP III], 2001).

Building HDL-C management into current practice
The guidance in ATP III, which is perhaps the most comprehensive current guidance regarding secondary lipid strategy, reinforces the consensus that where risk of CHD is >2 % per year, LDL- C is still the prime target. However, after optimal progress towards target LDL-C is achieved, the dyslipidaemia of the metabolic syndrome becomes a secondary target (ATP III, 2001).

ATP-III sees triglycerides as an independent risk factor with an intervention level at or above 2.3mmol/l and three levels of LDL-C and non-HDL-C target, depending upon the exact level of CHD risk (see Table 2). No target level for HDL-C is given, though, because triglycerides and HDL-C are linked. The European Consensus panel has provided a general target for HDL-C of >1.03 mmol/l.

Management strategies
Management options in CHD, metabolic syndrome and diabetes are given in Table 3. The first management strategy is behavioural – appropriate diet, weight loss, exercise and smoking cessation. Dietary fat is also a key consideration with an emphasis on reducing saturated fats:

  • total fat should be in the range 25–30 %
  • saturated fat <7 % of total calories 
  • polyunsaturated fat up to 10 % of total calories 
  • monounsaturated fat up to 20 % of total calories.

In practice, most of this will already have been done when reducing overall CHD risk and introducing a statin. After this, where maximal tolerable statin levels have been reached yet LDL-C targets are not achieved, ATP III (2001) suggests treatments that target HDL-C and triglycerides should be considered. Target lipid levels for triglycerides and HDL-C from the Joint European Societies and the European Consensus Panel are shown in Table 1.

Conclusion
The level of guidance suggested by ATP-III (2001) is perhaps too complex for everyday general practice; but the targets regarding triglycerides and HDL-C are eminently practical. The emerging consensus demonstrates that at all levels of cardiovascular risk, after reduction of LDL-C, strategies which lower triglycerides and raise HDL-C have an important preventive role.

REFERENCES:

American Diabetes Association (2004) Dyslipidaemia management in adults with diabetes. Diabetes Care 27(Suppl 1): S68–71
British Medical Association (2003) Investing in General Practice. The New General Medical Services Contract. BMA, London
Brown G, Albers JJ, Fisher LD et al (1990) Regression of coronary disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New England Journal of Medicine 323: 1289–98 
Department of Health (2000) National Service Framework for Coronary Heart Disease. Department of Health, London European Consensus Panel on HDL-C (2004) Raising high- density lipoprotein cholesterol with reduction of cardiovascular risk. Current medical Research and Opinion 20: 1268(16) 
Expert Panel in Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 285: 2486–97
Gordon DJ, Probstfield PL, Garrison RJ (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15
Gordon DJ, Rifkind BM (1989) High-density lipoprotein – the clinical implications of recent studies. New England Journal of Medicine 321: 1311–16
Hennekens CH, Ridker PM, Eds (1999) Clinical trials in cardiovascular disease: a companion to Braunwald’s Heart Disease.Section 2. Treatment trials. Philadelphia, WB Saunders: 206
Insull W, McGovern ME, Schrott H, Thompson P, Crouse JR, Zeive F, Conbelli J (2004) Efficacy of extended-release niacin with lovastatin for hypercholesterolaemia: assessing all reasonable doses with innovative surface graph analysis. Archives of International Medicine 164: 1121–27
Mosca L, Appel LJ, Benjamin EJ et al (2004) Evidence-based guidelines for cardiovascular disease prevention in women.Circulation 109: 672–93
Phillips NR, Waters D, Havel RJ (1993) Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88: 2762–70
Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New England Journal of Medicine 341: 410–18
Second Joint Tast Force of European and other Societies on Coronary Prevention (1998) Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.European Heart Journal 19: 1434–503
Sharrett AR, Ballantyne CM, Coady SA et al (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL subfractions. The Atherosclerosis Risk In Communities (ARIC) Study. Circulation 104: 1108–13
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double- blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–17
Watkins PJ (2003) Cardiovascular disease, hypertension, and lipids. British Medical Journal 326: 874 –76

Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.
© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.